Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term extension study of dersimelagon in EPP or XLP
NL-OMON59673Phase 3Active, not recruiting
- Sponsor
- Mitsubishi Tanabe Pharma America
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dersimelagon in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), sponsored by Mitsubishi Tanabe Pharma America. Primary endpoints: Treatment-emergent adverse events, Physical examination and 4 more. Started Jul 2025; status: active, not recruiting.
02
Drugs
dersimelagon
03
Conditions
erythropoietic protoporphyria (EPP)X-linked protoporphyria (XLP)
Beyond the preview
Go deeper on NL-OMON59673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59673.